Company intelligence / Profile preview

Tactile Therapeutics, Inc.

California, United Statesgeneralinception.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Tactile Therapeutics is developing a pipeline of small molecule degraders aimed at proteins involved in necroptosis. As of late 2024, there are no disclosed clinical results or active clinical trials; the company appears to be in the pre-clinical stage with a focus on translational research and early development.

Therapeutic areas: Immunology
Modalities: Small molecule degraders
Industry: Biotech

Beyond the preview

Go deeper on Tactile Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tactile Therapeutics, Inc..

Explore the full profile